Cited by 15,011Multiple Sclerosis Research StudiesHealth Systems, Economic Evaluations, Quality of LifeVoice and Speech Disorders

The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index.

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Kurtzke, John F.·1983·Neurology

DOI 10.1212/wnl.33.11.1444

Open this paper in CoChat — free account

Abstract

One method of evaluating the degree of neurologic impairment in MS has been the combination of grades (0 = normal to 5 or 6 = maximal impairment) within 8 Functional Systems (FS) and an overall Disability Status Scale (DSS) that had steps from 0 (normal) to 10 (death due to MS). A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 . . . 9) now divided into two (1.0, 1.5, 2.0 . . . 9.5). The lower portion is obligatorily defined by Functional System grades. The FS are Pyramidal, Cerebellar, Brain Stem, Sensory, Bowel & Bladder, Visual, Cerebral, and Other; the Sensory and Bowel & Bladder Systems have been revised. Patterns of FS and relations of FS by type and grade to the DSS are demonstrated.

Integrity signals

Registry

Crossref · 10.1212/wnl.33.11.1444

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

On the evaluation of disability in multiple sclerosis
Kurtzke, J. F. (1961) · Neurology · doi:10.1212/wnl.11.8.686 · Cited by 330
Further notes on disability evaluation in multiple sclerosis, with scale modifications
Kurtzke, J. F. (1965) · Neurology · doi:10.1212/wnl.15.7.654 · Cited by 309
A New Scale for Evaluating Disability in Multiple Sclerosis
Kurtzke, J. F. (1955) · Neurology · doi:10.1212/wnl.5.8.580 · Cited by 305
Appreciating the consequences of disease: the international classification of impairments, disabilities, and handicaps.
Wood, P. (1980) · PubMed · Cited by 247
NEUROLOGIC IMPAIRMENT IN MULTIPLE SCLEROSIS AND THE DISABILITY STATUS SCALE
Kurtzke, J. F. (1970) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1970.tb05808.x · Cited by 156
A PROPOSAL FOR A UNIFORM MINIMAL RECORD OF DISABILITY IN MULTIPLE SCLEROSIS
Kurtzke, J. F. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb05548.x · Cited by 127
STUDIES ON THE NATURAL HISTORY OF MULTIPLE SCLEROSIS 6. Clinical and Laboratory Findings at First Diagnosis
Kurtzke, J. F., Beebe, G. W., Nagler, B., Auth, T. L., Kurland, L. T., & Nefzger, M. D. (1972) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1972.tb07525.x · Cited by 68
THE SOCIO-ECONOMIC SCALE
Mellerup, E., Fog, T., Raun, N. E., Colville, P., de Rham, B., Hannah, B., & Kurtzke, J. F. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb05549.x · Cited by 53
The effects of isoniazid on patients with multiple sclerosis; preliminary report.
Kurtzke, J. F., & Berlin, L. (1954) · PubMed · doi:10.1164/art.1954.70.4.577 · Cited by 23
ACUTE RESPIRATORY FAILURE IN MULTIPLE SCLEROSIS AND ITS MANAGEMENT
Guthrie, T. C., Kurtzke, J. F., & BERLIN, L. (1952) · Annals of Internal Medicine · doi:10.7326/0003-4819-37-6-1197 · Cited by 20

Show all 13 references

Sorted by citations

Items 401–500 of 1,135

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
Giovannoni, G., Cook, S. D., Rammohan, K. W., Rieckmann, P., Sørensen, P. S., Vermersch, P., Hamlett, A., Viglietta, V., & Greenberg, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70023-0 · Cited by 252
What drives quality of life in multiple sclerosis?
Hemmett, L., Holmes, J., Barnes, M., & Russell, N. (2004) · QJM · doi:10.1093/qjmed/hch105 · Cited by 255
Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease
Azevedo, C. J., Cen, S., Khadka, S., Liu, S., Kornak, J., Shi, Y., Zheng, L., Hauser, S. L., & Pelletier, D. (2018) · Annals of Neurology · doi:10.1002/ana.25150 · Cited by 250
Quality of Life in Multiple Sclerosis
Rudick, R. A. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530360035014 · Cited by 252
Symptomatic therapy and neurorehabilitation in multiple sclerosis
Kesselring, J., & Beer, S. M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70193-9 · Cited by 250
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
Filippi, M., Rovaris, M., Inglese, M., Barkhof, F., Stefano, N. D., Smith, S. M., & Comi, G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17271-1 · Cited by 251
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis
Leppert, D. (1998) · Brain · doi:10.1093/brain/121.12.2327 · Cited by 251
Interferon β-1a in primary progressive MS
Leary, S. M., Miller, D., Stevenson, V. L., Brex, P., Chard, D., & Thompson, A. J. (2003) · Neurology · doi:10.1212/wnl.60.1.44 · Cited by 250
Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)
Sharrack, B., Saccardi, R., Alexander, T., Badoglio, M., Burman, J., Farge, D., Greco, R., Jessop, H., Kazmi, M. A., Киргизов, К. И., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0684-0 · Cited by 262
Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern
Kroencke, D. C., Lynch, S. G., & Denney, D. R. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600213 · Cited by 253
The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis
Vercoulen, J. H. M. M., Swanink, C. M. A., Galama, J. M. D., Fennis, J. F. M., Jongen, P. J., Hommes, O. R., van der Meer, J. W. M., & Bleijenberg, G. (1998) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(98)00023-3 · Cited by 248
Azathioprine
Costanzi, C., Matiello, M., Lucchinetti, C. F., Weinshenker, B. G., Pittock, S. J., Mandrekar, J. N., Thapa, P., & McKeon, A. B. (2011) · Neurology · doi:10.1212/wnl.0b013e31822a2780 · Cited by 248
In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI
Mainero, C., Benner, T., Radding, A., van der Kouwe, A. J. W., Jensen, R., Rosen, B. R., & Kinkel, R. P. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b64bf7 · Cited by 250
Structural brain abnormalities in multiple sclerosis patients with major depression
Feinstein, A., Roy, P., Lobaugh, N., Feinstein, K., O’Connor, P., & Black, S. (2004) · Neurology · doi:10.1212/01.wnl.0000110316.12086.0c · Cited by 294
The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis
Stone, L. A., Frank, J. A., Albert, P. S., Bash, C. N., Smith, M. E., Maloni, H. W., & McFarland, H. F. (1995) · Annals of Neurology · doi:10.1002/ana.410370511 · Cited by 247
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
Johnson, K. P., Brooks, B., Ford, C. C., Goodman, A. D., Guarnaccia, J. B., Lisak, R. P., Myers, L. W., PANITCH, H. S., Pruitt, A. A., ROSE, J. W., et al. (2000) · Multiple Sclerosis Journal · doi:10.1177/135245850000600407 · Cited by 247
Astrocytic damage is far more severe than demyelination in NMO
Takano, R., Misu, T., Takahashi, T., Sato, S., Fujihara, K., & Itoyama, Y. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e2414b · Cited by 246
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Pache, F. C., Zimmermann, H. G., Mikolajczak, J., Schumacher, S., Lacheta, A., Oertel, F. C., Bellmann–Strobl, J., Jarius, S., Wildemann, B., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0720-6 · Cited by 250
Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients
Benito‐León, J., Morales, J. M., & Rivera‐Navarro, J. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.2002.00450.x · Cited by 246
Resting state networks change in clinically isolated syndrome
Roosendaal, S. D., Schoonheim, M. M., Hulst, H. E., Sanz‐Arigita, E., Smith, S. M., Geurts, J. J. G., & Barkhof, F. (2010) · Brain · doi:10.1093/brain/awq058 · Cited by 257
Smoking and Disease Progression in Multiple Sclerosis
Healy, B. C., Ali, E. N., Guttmann, C. R. G., Chitnis, T., Glanz, B. I., Buckle, G. J., Houtchens, M. K., Stazzone, L., Moodie, J., Berger, A. M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.122 · Cited by 245
Depression in multiple sclerosis: Review and theoretical proposal
Arnett, P. A., Barwick, F. H., & BEENEY, J. E. (2008) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617708081174 · Cited by 243
Mobility, Balance and Falls in Persons with Multiple Sclerosis
Sosnoff, J. J., Socie, M. J., Boes, M. K., Sandroff, B. M., Pula, J. H., Suh, Y., Weikert, M., Balantrapu, S., Morrison, S., & Motl, R. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028021 · Cited by 244
Effects of a 6-month exercise program on patients with multiple sclerosis
Romberg, A., Virtanen, A., Ruutiainen, J., Aunola, S., Karppi, S. ‐., Vaara, M., Surakka, J., Pohjolainen, T., & Seppänen, A. (2004) · Neurology · doi:10.1212/01.wnl.0000145761.38400.65 · Cited by 244
A Two-Year Trial of Oleic and Erucic Acids (“Lorenzo's Oil”) as Treatment for Adrenomyeloneuropathy
Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.-C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291101 · Cited by 242
Locus for severity implicates CNS resilience in progression of multiple sclerosis
International Multiple Sclerosis Genetics Consortium, Harroud, A., Stridh, P., McCauley, J. L., Saarela, J., van den Bosch, A. M. R., Engelenburg, H. J., Beecham, A. H., Alfredsson, L., Alikhani, K., et al. (2023) · Nature · doi:10.1038/s41586-023-06250-x · Cited by 243
Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder
Ringelstein, M., Ayzenberg, I., Harmel, J., Lauenstein, A.-S., Lensch, E., Stögbauer, F., Hellwig, K., Ellrichmann, G., Stettner, M., Chan, A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0533 · Cited by 242
Neurofilament and glial fibrillary acidic protein in multiple sclerosis
Norgren, N., Sundström, P., Svenningsson, A., Rosengren, L., Stigbrand, T. I., & Gunnarsson, M. (2004) · Neurology · doi:10.1212/01.wnl.0000142988.49341.d1 · Cited by 242
Physical rehabilitation has a positive effect on disability in multiple sclerosis patients
Solari, A., Filippini, G., Gascó, P., Colla, L., Salmaggi, A., Mantia, L. L., Farinotti, M., Eoli, M., & Mendozzi, L. (1999) · Neurology · doi:10.1212/wnl.52.1.57 · Cited by 238
Fatigue in multiple sclerosis is related to disability, depression and quality of life
Pittion‐Vouyovitch, S., Debouverie, M., Guillemin, F., Vandenberghe, N., Anxionnat, R., & Vespignani, H. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.11.025 · Cited by 246
Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis
Nortvedt, M. W., Riise, T., Frugaård, J., Mohn, J., Bakke, Å., Skår, A. B. R., Nyland, H., Glad, S. B., & Myhr, K.-M. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458506071210 · Cited by 240
Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey
Hadjimichael, O., Vollmer, T., & Oleen-Burkey, M. (2008) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-6-100 · Cited by 240
Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis.
Mohr, D. C., Likosky, W., Bertagnolli, A., Goodkin, D. E., Wende, J. V. D., Dwyer, P., & Dick, L. P. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.68.2.356 · Cited by 240
Cognitive impairment in different MS subtypes and clinically isolated syndromes
Potagas, C. M., Giogkaraki, E., Koutsis, G., Mandellos, D., Tsirempolou, E., Sfagos, C. A., & Vassilopoulos, D. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.10.002 · Cited by 240
Dynamic I maging of I ndividual R emyelination P rofiles in M ultiple S clerosis
Bodini, B., Veronese, M., García-Lorenzo, D., Battaglini, M., Poirion, É., Chardain, A., Freeman, L. A., Louapre, C., Tchikviladzé, M., Papeix, C., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24620 · Cited by 247
Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesions
Smith, M. E., Stone, L. A., Albert, P. S., Frank, J. A., Martinꝉ, R., Armstrong, M. M., Maloni, H. W., McFarlin, D. E., & McFarland, H. F. (1993) · Annals of Neurology · doi:10.1002/ana.410330511 · Cited by 240
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Tuohy, O., Costelloe, L., Hill-Cawthorne, G., Bjornson, I., Harding, K., Robertson, N., May, K., Button, T., Azzopardi, L., Kousin-Ezewu, O., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307721 · Cited by 238
Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis.
Cercignani, M., Inglese, M., Pagani, E., Comi, G., & Filippi, M. (2001) · PubMed Central · Cited by 234
An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography
Henderson, A. P. D., Trip, S. A., Schlottmann, P. G., Altmann, D. R., Garway‐Heath, D. F., Plant, G. T., & Miller, D. (2007) · Brain · doi:10.1093/brain/awm285 · Cited by 239
Regional grey matter atrophy in clinically isolated syndromes at presentation
Henry, R. G., Shieh, M., Okuda, D. T., Evangelista, A., Gorno‐Tempini, M., & Pelletier, D. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.134825 · Cited by 238
Two subsets of dendritic cells are present in human cerebrospinal fluid
Pashenkov, M. V., Huang, Y.-M., Kostulas, V., Haglund, M., Söderström, M. B., & Link, H. (2001) · Brain · doi:10.1093/brain/124.3.480 · Cited by 238
Cognitive functioning in children and adolescents with multiple sclerosis
MacAllister, W. S., Belman, A. L., Milazzo, M. C., Weisbrot, D. M., Christodoulou, C., SCHERL, W. F., Preston, T., Cianciulli, C., & Krupp, L. (2005) · Neurology · doi:10.1212/01.wnl.0000158474.24191.bc · Cited by 237
Optical coherence tomography in multiple sclerosis
Siger, M., Dziegielewski, K., Jasek, Ł., Bieniek, M., Nicpan, A., Nawrocki, J., & Selmaj, K. W. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0985-5 · Cited by 236
Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial
Beck, R. W., Gal, R. L., Bhatti, M. T., Brodsky, M. C., Buckley, E. G., Chrousos, G. A., Corbett, J. J., Eggenberger, E., Goodwin, J., Katz, B., et al. (2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(03)00862-6 · Cited by 236
Cortical atrophy is relevant in multiple sclerosis at clinical onset
Calabrese, M., Atzori, M., Bernardi, V., Morra, A., Romualdi, C., Rinaldi, L., McAuliffe, M., Barachino, L., Perini, P., Fischl, B. R., et al. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0503-6 · Cited by 234
Reliability and validity of two self-report measures of impairment and disability for MS
Schwartz, C. E., Vollmer, T. L., & Lee, H. (1999) · Neurology · doi:10.1212/wnl.52.1.63 · Cited by 234
Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis
Ehrenreich, H., Fischer, B., Norra, C., Schellenberger, F., Stender, N., Stiefel, M., Sirén, A., Paulus, W., Nave, K., Gold, R., et al. (2007) · Brain · doi:10.1093/brain/awm203 · Cited by 236
Health-related quality of life in multiple sclerosis
Berrigan, L. I., Fisk, J. D., Patten, S. B., Tremlett, H. L., Wolfson, C. M., Warren, S., Fiest, K. M., McKay, K. A., Marrie, R. A., For the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS), et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002564 · Cited by 236
Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis
Strober, L. B., DeLuca, J., Benedict, R. H. B., Jacobs, A., Cohen, J. A., Chiaravalloti, N. D., Hudson, L. D., Rudick, R. A., & LaRocca, N. G. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518808204 · Cited by 236
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
Simpson, S., Brouwer, E. D., Kalincik, T., Rijke, N., Hillert, J. A., Walton, C., Edan, G., Moreau, Y., Spelman, T., Geys, L., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012753 · Cited by 236
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis
Whitaker, J., McFarland, H., Rudge, P., & Reingold, S. C. (1995) · Multiple Sclerosis Journal · doi:10.1177/135245859500100107 · Cited by 236
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning
Ratchford, J. N., Saidha, S., Sotirchos, E. S., Oh, J., Seigo, M. A., Eckstein, C. P., Durbin, M. K., Oakley, J. D., Meyer, S. A., Conger, A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31827b1a1c · Cited by 235
The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials
Rudick, R. A., Cutter, G., & Reingold, S. C. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms845oa · Cited by 235
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
for the AFFIRM and SENTINEL Investigators, Hutchinson, M., Kappos, L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Galetta, S. L., Havrdová, E., LUBLIN, F. D., Miller, D. H., et al. (2009) · Journal of Neurology · doi:10.1007/s00415-009-0093-1 · Cited by 238
High concurrent presence of disability in multiple sclerosis
Johansson, S., Ytterberg, C., Claesson, I. M., Lindberg, J., Hillert, J. A., Andersson, M., Holmqvist, L. W., & von Koch, L. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0431-5 · Cited by 234
Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing–remitting MS
Morgen, K., Sammer, G., Courtney, S. M., Wolters, T., Melchior, H., Blecker, C. R., Oschmann, P., Kaps, M., & Vaitl, D. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.10.032 · Cited by 237
Falls in people with MS—an individual data meta-analysis from studies from Australia, Sweden, United Kingdom and the United States
Nilsagård, Y. E., Gunn, H., Freeman, J. A., Hoang, P. D., Lord, S. R., Mazumder, R., & Cameron, M. H. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514538884 · Cited by 234
X-linked adrenoleukodystrophy in women: A cross-sectional cohort study
Engelen, M., Barbier, M., Dijkstra, I. M. E., Schür, R., de Bie, R. M. A., Verhamme, C., Dijkgraaf, M. G. W., Aubourg, P. A., Wanders, R. J. A., van Geel, B. M., et al. (2014) · Brain · doi:10.1093/brain/awt361 · Cited by 234
Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis
Waubant, E. L., Goodkin, D., Gee, L., Bacchetti, P., Sloan, R., Stewart, T. J., Andersson, P.-B., Stabler, G., & Miller, K. (1999) · Neurology · doi:10.1212/wnl.53.7.1397 · Cited by 234
A prospective study of patterns of fatigue in multiple sclerosis
Lerdal, A., Celius, E. G., Krupp, L., & Dahl, A. A. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01974.x · Cited by 235
T2 Hypointensity in the Deep Gray Matter of Patients With Multiple Sclerosis
Bakshi, R., Benedict, R. H. B., Bermel, R. A., Caruthers, S. D., Puli, S. R., Tjoa, C. W., Fabiano, A. J., & Jacobs, L. R. (2002) · Archives of Neurology · doi:10.1001/archneur.59.1.62 · Cited by 231
The impact of inpatient rehabilitation on progressive multiple sclerosis
Freeman, J. A., Langdon, D. W., Hobart, J. C., & Thompson, A. J. (1997) · Annals of Neurology · doi:10.1002/ana.410420216 · Cited by 231
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis
Ramanathan, S., Reddel, S., Henderson, A. P. D., Parratt, J. D. E., Barnett, M. H., Gatt, P. N., Merheb, V., Kumaran, R.-Y. A., Pathmanandavel, K., Sinmaz, N., et al. (2014) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000040 · Cited by 234
The clinical course of multiple sclerosis
Confavreux, C., & Vukusic, S. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52001-2.00014-5 · Cited by 232
Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test
Sepulcre, J., Vanotti, S., Hernández, R., Sandoval, G., Cáceres, F., Garcea, O., & Villoslada, P. (2006) · Multiple Sclerosis Journal · doi:10.1191/1352458506ms1258oa · Cited by 231
Multiple sclerosis-associated fatigue
Krupp, L., Serafin, D., & Christodoulou, C. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.99 · Cited by 241
The progress of cognitive decline in multiple sclerosis. A controlled 3- year follow-up
Kujala, P. (1997) · Brain · doi:10.1093/brain/120.2.289 · Cited by 231
Slowed Information Processing in Multiple Sclerosis
Litvan, I., Grafman, J. H., Vendrell, P., & Martinez, J. M. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520270059021 · Cited by 231
Brain MRI lesions and atrophy are related to depression in multiple sclerosis
Bakshi, R., Czarnecki, D., Shaikh, Z. A., Priore, R. L., Janardhan, V., Kaliszky, Z., & Kinkel, P. R. (2000) · Neuroreport · doi:10.1097/00001756-200004270-00003 · Cited by 230
Meta-Analysis of Three Different Types of Fatigue Management Interventions for People with Multiple Sclerosis: Exercise, Education, and Medication
Asano, M., & Finlayson, M. L. (2014) · Multiple Sclerosis International · doi:10.1155/2014/798285 · Cited by 245
Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis
Amato, M. P., Portaccio, E., Goretti, B., Zipoli, V., Battaglini, M., Bartolozzi, M. L., Stromillo, M. L., Guidi, L., Siracusa, G., Sorbi, S., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.8.1157 · Cited by 226
Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis
Runia, T. F., Hop, W. C. J., de Rijke, Y. B., Buljevac, D., & Hintzen, R. Q. (2012) · Neurology · doi:10.1212/wnl.0b013e31825fdec7 · Cited by 230
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations
Petzold, A. (2002) · Brain · doi:10.1093/brain/awf165 · Cited by 230
Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI
Dal‐Bianco, A., Grabner, G., Kronnerwetter, C., Weber, M., Kornek, B., Kasprian, G. J., Berger, T., Leutmezer, F., Rommer, P. S., Trattnig, S., et al. (2020) · Brain · doi:10.1093/brain/awaa436 · Cited by 230
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
Steinman, L., Fox, E., Hartung, H., Álvarez, E., Qian, P., Wray, S. E., Robertson, D. S., Huang, D., Selmaj, K. W., Wynn, D. R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201904 · Cited by 249
Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI
Filippi, M., Iannucci, G., Tortorella, C., Minicucci, L., Horsfield, M. A., Colombo, B., Sormani, M. P., & Comı, G. (1999) · Neurology · doi:10.1212/wnl.52.3.588 · Cited by 227
Sleep and fatigue in multiple sclerosis
Stanton, B. R., Barnes, F. P., & Silber, E. (2006) · Multiple Sclerosis Journal · doi:10.1191/135248506ms1320oa · Cited by 229
Kinematic analysis of thalamic versus subthalamic neurostimulation in postural and intention tremor
Herzog, J., Hamel, W., Wenzelburger, R., Pötter, M., Pinsker, M. O., Bartussek, J., Morsnowski, A., Steigerwald, F., Deuschl, G., & Volkmann, J. (2007) · Brain · doi:10.1093/brain/awm077 · Cited by 229
Spinal cord atrophy and disability in MS
Stevenson, V. L., Leary, S. M., Losseff, N. A., Parker, G. J. M., Barker, G. J., Husmani, Y., Miller, D. H., & Thompson, A. J. (1998) · Neurology · doi:10.1212/wnl.51.1.234 · Cited by 229
Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.
Genç, K., Dona, D. L., & Reder, A. T. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119455 · Cited by 228
Gut microbiota–specific IgA + B cells traffic to the CNS in active multiple sclerosis
Pröbstel, A., Zhou, X., Baumann, R., Wischnewski, S., Kutza, M., Rojas, O. L., Sellrie, K., Bischof, A., Kim, K., Ramesh, A., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc7191 · Cited by 240
Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis
Schoonheim, M. M., Hulst, H. E., Brandt, R. B., Strik, M., Wink, A. M., Uitdehaag, B. M. J., Barkhof, F., & Geurts, J. J. G. (2015) · Neurology · doi:10.1212/wnl.0000000000001285 · Cited by 229
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
Polman, C. H., Barkhof, F., Sandberg‐Wollheim, M., Linde, A., Nordle, Ö., & Nederman, T. (2005) · Neurology · doi:10.1212/01.wnl.0000154520.48391.69 · Cited by 227
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis
Palanichamy, A., Apeltsin, L., Kuo, T. C., Sirota, M., Wang, S., Pitts, S. J., Sundar, P. D., Telman, D., Zhao, L., Derstine, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008930 · Cited by 225
The burden of multiple sclerosis: A community health survey
Jones, C. A., Pohar, S. L., Warren, S., Turpin, K. V. L., & Warren, K. G. (2008) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-6-1 · Cited by 226
Progressive cerebral atrophy in MS
Fox, N. C., Jenkins, R., Leary, S. M., Stevenson, V. L., Losseff, N. A., Crum, W. R., Harvey, R. J., Rossor, M. N., Miller, D. H., & Thompson, A. J. (2000) · Neurology · doi:10.1212/wnl.54.4.807 · Cited by 226
Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study.
Rovaris, M., Bozzali, M., Iannucci, G., Ghezzi, A., Caputo, D., Montanari, E., Bertolotto, A., Bergamaschi, R., Capra, R., Mancardi, G., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.9.1406 · Cited by 221
Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study
Wuerfel, J. T. (2003) · Brain · doi:10.1093/brain/awh007 · Cited by 225
Effect of Aerobic Training on Walking Capacity and Maximal Exercise Tolerance in Patients With Multiple Sclerosis: A Randomized Crossover Controlled Study
Rampello, A., Franceschini, M., Piepoli, M. F., Antenucci, R., Lenti, G., Olivieri, D., & Chetta, A. A. (2007) · Physical Therapy · doi:10.2522/ptj.20060085 · Cited by 225
Treatment of multiple sclerosis with Copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation
Miller, A., Shapiro, S., Gershtein, R., Kinarty, A., Rawashdeh, H., Honigman, S., & Lahat, N. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00191-x · Cited by 225
Memory impairment in multiple sclerosis: A quantitative review.
Thornton, A. E., & Raz, N. (1997) · Neuropsychology · doi:10.1037/0894-4105.11.3.357 · Cited by 225
Cortical and subcortical influences on clustering and switching in the performance of verbal fluency tasks
Tröster, A. I., Fields, J. A., Testa, J. A., Paul, R. H., Blanco, C. R., Hames, K. A., Salmon, D. P., & Beatty, W. W. (1998) · Neuropsychologia · doi:10.1016/s0028-3932(97)00153-x · Cited by 231
Neuropsychiatric Manifestations of Multiple Sclerosis
Dı́az-Olavarrieta, C., Cummings, J. L., Velazquez, J., & de al Cadena, C. G. (1999) · Journal of Neuropsychiatry · doi:10.1176/jnp.11.1.51 · Cited by 224
Interferon beta-1b in secondary progressive MS
Kappos, L., Weinshenker, B. G., Pozzilli, C., Thompson, A. J., Dahlke, F., Beckmann, K., Polman, C. H., & McFarland, H. F. (2004) · Neurology · doi:10.1212/01.wnl.0000145561.08973.4f · Cited by 224
Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years
Bagnato, F. R. (2003) · Brain · doi:10.1093/brain/awg182 · Cited by 224
Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT.
Schulz, J. B., Klockgether, T., Petersen, D., Jauch, M., Müller-Schauenburg, W., Spieker, S., Voigt, K., & DICHGANS, J. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.9.1047 · Cited by 223
Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis
Wiles, C. M. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.2.174 · Cited by 222
Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis
Fernando, K. (2004) · Brain · doi:10.1093/brain/awh153 · Cited by 220
The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis
Zamboni, P., Menegatti, E., Galeotti, R., Malagoni, A. M., Tacconi, G., Dall'Ara, S., Bartolomei, I., & Salvi, F. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.11.027 · Cited by 219
Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis
Matsushita, T., Tateishi, T., Isobe, N., Yonekawa, T., Yamasaki, R., Matsuse, D., Murai, H., & Kira, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061835 · Cited by 226

Authors: Kurtzke, J. F.
Affiliations: Georgetown University (US)
Corresponding author: Kurtzke, John F.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1983-11
Volume: 33
Issue: 11
Pages: 1444-1444
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.33.11.1444
OpenAlex: W2112165124
Cited by: 15,011
References: 13
Citations by year: 2026: 474 · 2025: 622 · 2024: 692 · 2023: 648 · 2022: 722 · 2021: 781 · 2020: 764 · 2019: 648 · 2018: 603 · 2017: 592 · 2016: 657 · 2015: 634 · 2014: 632 · 2013: 586 · 2012: 581
FWCI: 9.57
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Health Sciences › Health Professions › Speech and Hearing › Voice and Speech Disorders
Keywords: multiple sclerosis, Expanded Disability Status Scale, disability assessment, neurological deficit, functional systems, pyramidal system, cerebellar function, brainstem, sensory impairment, bowel and bladder dysfunction, visual impairment
MeSH terms: Humans, Multiple Sclerosis, Nervous System Diseases, Neurologic Examination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks